The Non-Small Cell Lung Cancer Market is estimated to be valued at US$ 27252.31 Mn in 2023 and is expected to exhibit a CAGR of 9.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. It usually develops in the outer parts of the lungs. The three main types of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Advances in targeted therapies and immunotherapies have vastly improved treatment outcomes for certain patients with advanced non-small cell lung cancer.

Market key trends:
One of the major trends in the non-small cell lung cancer market size is the emergence of immunotherapy as an effective treatment option. Immunotherapy is playing an increasingly important role in the treatment of patients, either alone or in combination with other therapies like chemotherapy or targeted therapies. Immunotherapies stimulate the body's own immune system to recognize and destroy cancer cells more effectively. Drugs like checkpoint inhibitors that target molecules like PD-1 and PD-L1 have received approvals for treating various types and stages of NSCLC and are becoming standard regimens. The improving survival benefits, durable responses, and relatively less toxicity compared to chemotherapy have boosted the adoption of immunotherapy in NSCLC treatment.

Porter's Analysis

Threat of new entrants: The threat of new entrants is moderate in this market as there are huge capital investments required for R&D. However, emerging biotech companies try to develop innovative drugs to enter.

Bargaining power of buyers: The bargaining power of buyers is high since many generic drugs are available for lung cancer treatment. Buyers can negotiate for price reductions with companies.

Bargaining power of suppliers: Suppliers of raw materials have moderate bargaining power since most materials used are common. However, key suppliers of innovative compounds have some power.

Threat of new substitutes: Threat of new substitutes is high as new treatment methods like immunotherapy are gaining popularity rapidly.

Competitive rivalry: The competitive rivalry is intense as major players compete to develop novel precision medicines and combination therapies.

SWOT Analysis

Strengths: Availability of targeted therapies, rise in drug approvals, growing demand for personalized medicines.

Weaknesses: High treatment costs, frequent relapse of the disease, adverse effects of therapies.

Opportunities: Emerging economies with growing healthcare spending, pipeline drugs in clinical trials, scope for biomarker-based combinations.

Threats: Safety issues regarding new agents, preference to alternative treatments, affordable generic competition.

Key Takeaways

The global non-small cell lung cancer market is expected to witness high growth, exhibiting CAGR of 9.4% over the forecast period, due to increasing incidence of lung cancer and approvals of premium-priced drugs. According to WHO, lung cancer led to over 1.8 million new cases and 1.6 million deaths globally in 2021.

Regionally, North America is expected to dominate the market owing to advanced healthcare infrastructure, presence of leading players, and high diagnosis and treatment rates. Asia Pacific is poised to witness fastest growth due to rising healthcare expenditure, growing patient volumes, and increasing focus of players.

Key players operating in the non-small cell lung cancer market are Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc. Major players focus on developing targeted drugs and biomarker-driven combination treatments through proprietary research to strengthen their product portfolios.

Get more insights on this topic: https://www.newswirestats.com/non-small-cell-lung-cancer-market-size-and-opportunity/